Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CBX7 | O95931 | 1/20 | 0.35 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.35 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.35 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16186530 | 0.89 | ALDH1A1 (0.39) | ALDH1A1KDM4EL3MBTL1HDAC6IDO1 | |
| SCHEMBL16186524 | 0.88 | ALDH1A1 (0.38) | ALDH1A1KDM4EL3MBTL1HDAC6IDO1 | |
| SCHEMBL16186528 | 0.88 | ALDH1A1 (0.40) | ALDH1A1KDM4EL3MBTL1HDAC6IDO1 | |
| SCHEMBL20082384 | 0.86 | KDM4E (0.42) | ALDH1A1KDM4EL3MBTL1IDO1MEN1 | |
| SCHEMBL20355705 | 0.85 | ALDH1A1 (0.42) | ALDH1A1KDM4EIDO1CBX7CDYL2 | |
| SCHEMBL29670894 | 0.80 | KMO (0.42) | IDO1HPGD | |
| SCHEMBL18329427 | 0.80 | KMO (0.42) | IDO1HPGD | |
| SCHEMBL20356853 | 0.80 | MEN1 (0.49) | ALDH1A1L3MBTL1MEN1GAAPKM | |
| SCHEMBL15157087 | 0.79 | KMT2A (0.45) | ALDH1A1KDM4EL3MBTL1IDO1MEN1 | |
| SCHEMBL16186523 | 0.75 | IDO1 (0.62) | ALDH1A1IDO1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426784-B2 | Imidazodiazepine compound | ASTELLAS PHARMA INC. (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180185383-A1 | IMIDAZODIAZEPINE COMPOUND | HTR1D, DRD2, DRD1 | ALDH1A1 1637/4885KDM4E 2920/4885L3MBTL1 3299/4885 |
| US-10426784-B2 | Imidazodiazepine compound | GRIN2D, HTR1D, DRD2 | ALDH1A1 1063/4885KDM4E 2841/4885L3MBTL1 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.